BRAF and acral lentiginous melanoma: Median PFS was 3.4 months (95% CI, 2.7–5.3) in patients with BRAF wild-type acral melanoma and 1.9 months (95% CI, 0.5–2.6) in patients with BRAF-mutant disease (Table 4).